303
Participants
Start Date
August 26, 2022
Primary Completion Date
July 1, 2029
Study Completion Date
July 1, 2029
Prospective determination of the clinical utility of measurable residual disease (MRD) testing
Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
Memorial Sloan Kettering Cancer Center, New York
New York Presbyterian / Weill Cornell Medical Center, New York
Roswell Park Comprehensive Cancer Center, Buffalo
Levine Cancer Institute, Charlotte
Northside Hospital, Atlanta
University of Miami, Miami
H. Lee Moffitt Cancer Center, Tampa
Vanderbilt University Medical Center, Nashville
The Ohio State University Comprehensive Cancer Center, Columbus
Cleveland Clinic, Cleveland
University of Chicago Medicine, Chicago
University of Colorado, Aurora
City of Hope, Duarte
University of California, San Francisco, San Francisco
Stanford University, Stanford
Fred Hutchinson Cancer Center, Seattle
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
National Marrow Donor Program
OTHER
Center for International Blood and Marrow Transplant Research
NETWORK